Suven Life Sciences Ltd has secured product patents for its clinical candidate SUVN-502 for Alzheimer's disease from several key countries like India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe. The granted product patent for SUVN-502 in all the countries is valid until June 2023.
The clinical candidate SUVN-502 is exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts. The granted patent has been validated in all the nine member countries of Eurasia (including Russia) and 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.
SUVN-502 completed the phase-I single ascending & multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested with excellent bioavailability and half life for potential once in a day treatment. Suven is planning to initiate the clinical phase-II proof-of-concept studies during 2010. The company targets launching of SUVN-502 in later part of 2013 or early part of 2014. Other molecules in the same category currently in development include GSK's molecule presently in phase-II.
Venkat Jasti, CEO of Suven, said, "We are very pleased by the grant of these patents at most of the key market countries for our clinical candidate SUVN-502 which is being developed for CNS disorders in the treatment of cognitive impairment, the unmet medical need. Potential market opportunity for these indications is more than US$20 billion globally. Granting of these patents to our clinical candidate is more timely and relevant now that the candidate is ready to enter into phase-II proof-of-concept clinical trials during 2010. SUVN-502 attracted lot of scientific and commercial interest from global pharma companies and few companies initiated due diligence process for potential partnering."